Funding for this research was provided by:
Eli Lilly and Company
Received: 16 January 2020
Accepted: 27 April 2020
First Online: 15 May 2020
Change Date: 2 July 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via the original article.
Ethics approval and consent to participate
: The studies were designed by the sponsor, Eli Lilly and Company, an academic advisory board that included non-Lilly authors of this manuscript, and Incyte Corp. The studies were conducted in accordance with ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines and were all approved by Quorum Review IRB as follows: RA-BEGIN (#27256), RA-BEAM (#27257), RA-BUILD (#27258), and RA-BEACON (#27259), and ethics approvals were also obtained for all additional sites for each trial. All patients provided written informed consent for both the long-term extension study as well as the vaccine sub-study.
: Not applicable.
: Paul Emery reports consulting fees from Pfizer, MSD, Abbvie, BMS, UCB, Roche, Novartis, Samsung, Sandoz, Eli Lilly and Company; Yoshiya Tanaka reports grant/research support from Asahi-kasei, Mitsubishi-Tanabe, Chugai, Takeda, Sanofi, Bristol-Myers, UCB, Daiichi-Sankyo, Eisai, and Ono and speaker/honoraria from Daiichi-Sankyo, Astellas, Chugai, Eli Lilly, Pfizer, Abbvie, YL Biologics, Bristol-Myers, Takeda, Mitsubishi-Tanabe, Novartis, Eisai, Janssen, and Teijin; Tracy Cardillo, Douglas Schlichting, Terence Rooney, Scott Beattie, and Cameron Helt are full-time employees of and own stock in Eli Lilly and Company; Josef Smolen reports personal fees and other from Eli Lilly and Company, AbbVie, Janssen, MSD, Novartis Pharma, Pfizer, personal fees and other from Roche, personal fees from Amgen, AstraZeneca, Astro, Bristol-Meyers Squibb, Celgene, Celltrion, Chugai Pharmaceutical, Gilead, ILTOO, Medimmune, Samsung, Sanofi-Aventis, UCB.